Market capitalization | JPY151.37b |
Enterprise Value | JPY550.26b |
PER (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 1.75 |
P/S ratio (TTM) P/S ratio | 0.48 |
P/B ratio (TTM) P/B ratio | 0.97 |
Dividend yield | 5.51% |
Last dividend (FY23) | JPY21.00 |
As a Free StocksGuide user, you can view scores for all 6,945 stocks worldwide.
7 Analysts have issued a Sumitomo Dainippon Pharma forecast:
7 Analysts have issued a Sumitomo Dainippon Pharma forecast:
Mar '24 | |
Current assets | 269,569 269,569 |
Fixed assets | 637,937 637,937 |
Total Assets | 907,506 907,506 |
Mar '24 | |
Equity | 156,136 156,136 |
Debt capital | 751,370 751,370 |
Total Capital | 907,506 907,506 |
In millions JPY.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Sumitomo Dainippon Pharma Co., Ltd. engages in manufacture, sale, import, and export of pharmaceutical products. It operates through the Pharmaceutical Business and Other Business segments. The Pharmaceutical Business segment manufactures and sells generic and prescription drugs in Japan, North America, China, and other overseas countries. The Other Business segment division includes food ingredients, additives, chemical products, veterinary drugs, and diagnostic reagents. The company was founded on May 14, 1897 and is headquartered in Osaka, Japan.
Head office | Japan |
CEO | Toru Kimura |
Employees | 4,980 |
Founded | 1897 |
Website | www.sumitomo-pharma.co.jp |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.